P21 (P021): Evidence, Mechanism & Legal Status

P021 (also written P21; chemical name Ac-DGGLAG-NH2) is a small synthetic peptidergic compound engineered to mimic the neurotrophic activity of ciliary neurotrophic factor (CNTF), and it is increasingly marketed in research-chemical channels as a "nootropic peptide."2 Its rodent data are real and reproducible; its human proof does not exist. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. P021 is an investigational, preclinical-only research compound with no human trials and no regulatory approval for human use anywhere; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published animal literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is P021 and how does it work?

P021 emerged from a reductionist drug-design program. Researchers began with Cerebrolysin, a porcine brain peptide mixture, isolated its neurotrophic epitope as an 11-residue "Peptide 6," then narrowed the minimal active region to a four-residue core, Ac-DGGL-NH2. To improve drug-likeness, an adamantylated glycine was appended at the C-terminus — increasing lipophilicity and blood-brain-barrier permeability and protecting against carboxypeptidase degradation — yielding the final compound Ac-DGGLAG-NH2, designated P021.21 The four-residue core corresponds to a biologically active region of human CNTF. PubChem lists the compound as CID 56599151 with molecular formula C27H42N6O8, consistent with the roughly 578 Da mass reported in the literature.9

Why a mimetic rather than CNTF itself? Full-length CNTF, around 22.8 kDa, does not efficiently cross the blood-brain barrier, has poor plasma stability, and provokes anti-CNTF antibody formation on systemic dosing. P021 was engineered specifically to retain the neurotrophic signal while avoiding those liabilities, and — unlike CNTF — has not elicited anti-CNTF antibody formation in animals.2

The mechanism, all of it preclinical, runs through two interlocking arms.26 First, a neurogenic arm: P021 competitively inhibits leukemia inhibitory factor (LIF) signaling, relieving LIF's suppression of neural-progenitor formation and thereby enhancing proliferation and differentiation of adult hippocampal dentate-gyrus progenitors. Second, a neurotrophic and anti-tau arm: P021 upregulates BDNF, which activates the TrkB-PI3K-AKT cascade; AKT phosphorylates GSK-3beta at the inhibitory Ser9 site. Because GSK-3beta is the major tau kinase, and contributes to amyloidogenic APP processing, lowering its activity reduces tau hyperphosphorylation at multiple Alzheimer-relevant sites and partially reduces amyloid-beta pathology.13 Downstream, treated animals show increased synaptic and plasticity markers and increased pCREB.1 P021 is reported orally bioavailable and stable in artificial gastric and intestinal juice, with blood-brain-barrier permeability corroborated by cerebrospinal-fluid tau-lowering after oral dosing; no formal human pharmacokinetic parameters have been published.5

What is the evidence by indication?

The entire P021 efficacy record is preclinical — animal and in-vitro. No human RCTs, cohort studies, or early-phase trials exist, a status confirmed by an independent 2025 review and by the absence of any registered study on ClinicalTrials.gov.8 Every indication below is therefore best understood as animal-model evidence, graded C at best.

The Alzheimer's evidence is the most developed. In the 3xTg-AD mouse model, chronic dietary P021 at 60 nmol per gram of feed, begun at 3 months and continued about 18 months, rescued the dentate-gyrus neurogenesis deficit (DCX-positive cells restored and exceeding wild-type, p less than 0.001; Ki-67 deficit rescued, p less than 0.0001), restored synaptic and dendritic markers, increased pCREB at 18 months, and reversed Morris-Water-Maze and object-location memory deficits.1 A separate 3xTg-AD study dosing at moderate-to-severe disease stages reported reduced tau hyperphosphorylation, attenuated soluble amyloid-beta, increased BDNF, and reduced neuroinflammation markers.43 A prenatal-to-early-postnatal dietary exposure rescued cognitive deficits and reduced tau hyperphosphorylation in 3xTg-AD offspring.7

In cognitive aging, 22-to-24-month-old Fisher rats given oral-gavage P021 at about 289 micrograms per kilogram per day for 88 days showed reduced age-dependent learning and memory decline, restored dentate-gyrus neurogenesis, increased BDNF, TrkB, and pCREB, and reduced the MR-spectroscopy aging marker myo-inositol.4 A follow-up showed oral P021 lowered total tau in aged-rat brain and CSF, confirming blood-brain-barrier penetrance and a measurable tau-lowering pharmacodynamic readout.5

What doses appear in the literature?

Reported strictly as information, not a protocol. No human dose, route, or schedule has ever been established or validated, so every figure here is an animal-study parameter.8 In the Alzheimer-model mouse work, P021 was given in the diet at about 60 nmol per gram of feed, yielding roughly 162 nmol per mouse per day, chronically for months.1 In aged rats, oral gavage delivered a 500 nM solution, about 289 micrograms per kilogram of body weight per day, for 88 days.4 The route studied is almost exclusively oral, by diet or gavage, exploiting the compound's reported oral stability and blood-brain-barrier permeability.2 Research-channel product is typically sold as a lyophilized powder for reconstitution, but no validated human reconstitution, dose, or administration guidance exists, and any such use would be of an unapproved substance.8

How safe is P021?

Human safety data are entirely absent, because no human has been studied in any trial — so the human safety profile is genuinely unknown.8 Preclinically, the rodent safety record is favorable as far as it goes: in the longest published exposure, roughly 18 months of dietary dosing in 3xTg-AD mice, investigators reported no weight loss, no tumors, and no signs of pain or overt toxicity, and unlike native CNTF, P021 did not induce anti-CNTF antibodies.1 The main unresolved concerns are theoretical. A review of anti-tau peptide drugs flagged possible anti-P021 antibody formation as a theoretical adverse event, though none has been observed to date.8 As with any agent that upregulates neurotrophic and progenitor-proliferation signaling, unintended proliferative or off-target effects cannot be excluded without human data, though no tumor signal appeared in long-term rodent dosing.1 Human reproductive safety is untested, and no human drug-interaction data exist. No contraindications are formally established, because no human safety data exist — and absence of toxicity in a single-lab rodent record is not evidence of human safety.8

What is the FDA and WADA status in 2026?

P021 is not approved for any indication and has no marketing authorization; it is an investigational, preclinical compound.8 It is not listed among FDA-recognized bulk drug substances eligible for 503A or 503B pharmacy compounding, and there is no FDA-approved label or prescribing information. It is sold only through research-chemical channels as "for laboratory or research use only, not for human consumption." Under the FDA's 2025 research-grade-peptide guidance, enforceable from January 2026, peptides shipped to individuals or marketed with dosing instructions are presumed intended for human use and are subject to enforcement regardless of "research use only" labeling.1413 P021 is reported as the lead candidate of Phanes Biotech for Alzheimer's and other neurodegenerative diseases, but as of 2026 the program remains early-stage with no registered human clinical trials, and composition-of-matter and use patents for the neurotrophic peptides exist.1110 P021 is not a DEA-controlled substance.

For athletes the picture is clear. P021 is not enumerated by name on the WADA Prohibited List, but as a pharmacological substance not approved by any governmental health authority for human therapeutic use, it falls under Section S0, Non-Approved Substances, which are prohibited at all times, both in and out of competition.12 Any athlete subject to WADA, USADA, or NCAA testing should treat P021 as banned.

Bottom line. P021 pairs a clean, coherent rodent neurotrophic and anti-tau evidence base with a near-total absence of human data. From a functional, do-no-harm standpoint, the gap between promise and proof is the headline — graded C, largely single-lab, with at least one negative model, FDA-unapproved, and WADA-prohibited under S0. Key uncertainties remain human pharmacokinetics, human safety including long-term immunogenic and proliferative risk, effective human dose and route, and whether the rodent signal translates at all. For now, P021 belongs to the laboratory, not the medicine cabinet. Regulatory facts here are current as of June 2026 and should be re-verified for any later date.